Abstract
AbstractPatients with myelofibrosis present a challenging clinical dilemma. The only curative therapy is allogeneic hematopoietic cell transplantation. Still, because of the variability in clinical course, comorbid medical conditions, and disease status, the decision to proceed is often difficult. Snyder and colleagues analyze a large cohort of patients with myelofibrosis receiving a common preparative regimen. The cohort presents patient and disease characteristics that predict outcomes. Their findings may allow for more accurate assessments of risk and benefit.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
